Navigation Links
Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of,GVAX Immunotherapy for Pancreatic Cancer

d survival, as well as the occurrence of adverse events and induction of immune response.

An earlier Phase 1 trial of GVAX immunotherapy for pancreatic cancer was conducted by the Johns Hopkins Sidney Kimmel Cancer Center in 14 patients who also received the immunotherapy following surgical resection of their tumor and standard adjuvant radiation and chemotherapy. As first reported in the Journal of Clinical Oncology in January 2001, three of eight patients who received the therapeutic dose levels of the immunotherapy had prolonged disease-free survival for a period of at least eight years. This outcome is considered particularly significant since all three long-term survivors were judged to be at high risk for recurrent cancer due to microscopic evidence of residual pancreatic tumor following surgery and two patients had metastatic tumor in regional lymph nodes. In addition, the three patients with prolonged disease-free survival -- but not the five who progressed and died -- showed evidence of treatment-associated antitumor immunity, including induction of T cell responses to the candidate tumor-associated antigen, mesothelin.

Pancreatic cancer is the fourth leading cause of cancer death in the United States. According to the American Cancer Society, approximately 37,170 Americans will be diagnosed with pancreatic cancer in 2007, and 33,370 are expected to die from the disease in 2007. Because symptoms are non-specific, cancer of the pancreas is rarely diagnosed at an early stage leaving surgical removal of the tumor as a treatment option for only approximately 20 to 30 percent of pancreatic cancer patients. The median survival of patients with operable cancer of the pancreas with currently available therapies is approximately 17 to 22 months.

Cell Genesys is focused on the development and commercialization of novel biological therapies for patients with cancer. The company is currently pursuing two clinical stage product platforms -- GVAX(TM)
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces a Broad, Patient-Specific Antibody Response
2. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
(Date:8/28/2015)... , FARUM, Denmark and ... On July 31, 2015 the US Food and Drug Administration ... of Major Depressive Disorder in adult patients who have failed ... current episode. TMS is a non-invasive technique for stimulating neural ... suffering from Major Depressive Disorder. The procedure has been proven ...
(Date:8/28/2015)... y LONDRES, 28 de agosto de ... PHIA) anunció hoy su participación en el  Congreso ... sus soluciones cardiológicas más recientes y novedosas, entre ... que conectan a las personas y la tecnología ... ayudar a diagnosticar, guiar los tratamientos y permitir ...
(Date:8/27/2015)... Aug. 27, 2015  A recent study by ... Journal, compared the Arthrosurface HemiCAP® Wave implant, which ... an "onlay" design implant for isolated patellofemoral disease. ... function and pain scores, none of the patients ... (OA). However, 53% of the patients in the ...
Breaking Medicine Technology:Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3
(Date:8/28/2015)... Madre, CA (PRWEB) , ... August 28, 2015 ... ... solutions to wound center management, Decatur County Memorial Hospital recently transitioned management companies ... model of Wound Center Management for their outpatient wound center. , Transitioning ...
(Date:8/28/2015)... ... August 28, 2015 , ... Approximately ... the Zoo to celebrate children helping children, a thank you to the many ... Ohio have contributed to the United Methodist initiative to end malaria deaths. , ...
(Date:8/28/2015)... ... August 28, 2015 , ... An article published August 19th ... LaRocco has gone through to open a pizzeria in Westchester. Mr. LaRocco was aware ... take several months, but the current process, having already gone on for over a ...
(Date:8/28/2015)... ... August 28, 2015 , ... For Dallas, the time is nearing for ... subsidiary USPI Tenet Health. , The American Heart Association hosts their well-known Heart Walk ... believe that together, a difference can be made. Walkers can participate in the cause ...
(Date:8/28/2015)... ... 2015 , ... As reported by Medical Daily on August 22 , ... that last for two years, the longest of any cellulite reduction system currently on ... a long-lasting, effective solution for their cellulite, according to Dr. Robert Weiss, director of ...
Breaking Medicine News(10 mins):Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3
... that the U.S. Department of Defense is funding to ... hospital patients from deadly infections, thanks to recent funding ... and Academic Research (NYSTAR). ,The funding comes as ... to treat, are on the rise. ,The ...
... UK recommendations for the availability of paracetamol, a common painkiller ... to limit the impact of excess doses of paracetamol, which ... drug is highly toxic to the liver in large amounts. ... to a maximum of 32 tablets of 500 mg each ...
... Volker Heussler of the Bernhard Nocht Institute for Tropical Medicine ... the immune system by killing the liver cell occupied by ... man, malarial parasites head to the liver and then to ... how the parasite avoids the immune system. Heussler's team used ...
... study on Rheumatic disease in women has shown that ... who have no genetic predisposition// to the disease. ... chronic inflammation of the joints. The cause of ... environmental factors is thought to trigger the immune system ...
... researchers found that altering the fatty acid ratio found in ... and decrease the amount of omega-6 fatty acids// may reduce ... in the Aug. 1 issue of the journal Clinical Cancer ... to show the impact of diet on lowering an inflammatory ...
... the brain of older patients with atrial fibrillation whether ... therapy// , according to a new study. ... from the University of California, San Francisco, Massachusetts General ... Boston University School of Medicine. ,Using a ...
Cached Medicine News:Health News:Device Can "Battle" Hospital Infections 2Health News:Device Can "Battle" Hospital Infections 3Health News:UK Recommendations On Painkillers Flaunted 2Health News:Altering Fatty Acid Levels in Diet May Reduce Prostate Cancer Growth Rate 2Health News:Risk of Brain Hemorrhage Rises with Old Age 2
Conventional Digitally-Controlled Water Baths...
... consists of two principal components. The AB5000 Console ... blood pumps and can be used either in ... hospitals. The AB5000 Ventricle is a disposable blood ... both ventricles of the heart and is designed ...
... The Dengue virus belongs to the Flavavirus ... commonly throughout the tropics.,Symptoms of Dengue fever ... pain in the back and limbs, lymphadenopathy,maculopapular ... for professional use as an aid in ...
... intracellular parasite Toxoplasma gondii and,may be contracted ... with cat,feces containing oocytes. If a pregnant ... the fetus through the placenta. This can ... of mortality and malformation.,This test is intended ...
Medicine Products: